Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine

Pharmacopsychiatry

Volumn 40, Issue 1, 2007, Pages 1-8

  Hofer, A ^a   Rettenbacher, M A ^a   Edlinger, M ^a   Huber, R ^a   Bodner, T ^a   Kemmler, G ^a   Sachs, G ^b   Fleischhacker, W W ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Amisulpride; Cognition; Employment; Needs; Olanzapine; Outcome; Quality of life; Schizophrenia

Indexed keywords

AMISULPRIDE; OLANZAPINE;

ADULT; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; EXCITEMENT; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA; SCORING SYSTEM; SOCIAL PSYCHOLOGY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VERBAL MEMORY;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OUTPATIENTS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR; SULPIRIDE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 34147178886     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-958520     Document Type: Article

References (49)

1. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR: Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441-449
2. Aschenberger S, Tucher O, Langer KW: Regensburger Wörtflüssigkeits-Test. Göttingen: Hogrefe Verlag für Psychologie, 2000
3. Awad AG, Voruganti LNP: Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004; 18: 877-893
4. Beasley CM, Tollefson GD, Tran PV: Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 1997; 58 (suppl 10): 7-12
5. Benton AS, Spreen O: Der Benton Test. Handbuch: 7. Auflage, 1996
6. Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT et al In vitro and in vivo biochemistry of olanzapine; a novel, atypical antipsychotic drug. J Clin Psychiatry 1997; 58 (suppl 10): 28-36
7. Corrigan PW, Reinke RR, Landsberger SA, Charate A, Toombs GA: The effects of atypical antipsychotic medications on psychosocial outcomes. Schizophr Res 2003; 63: 97-101
8. Delis DC, Kramer JH, Kaplan E, Ober BA: California Verbal Learning and Memory Test (Manual). San Antonio, TX: Psychological Corporation, 1987
9. Fleischhacker WW: Pharmacological treatment of schizophrenia: a review. In Maj M, Sartorius N, editors Schizophrenia. WPA Series Evidence and Experience in Psychiatry. Chichester, NY, Weinheim, Brisbane, Singapore, Toronto: John Wiley & Sons, LTD, 2002, p. 75-113
10. Foldemo A, Bogren L: Need assessment and quality of life in outpatients with schizophrenia: a 5-year follow-up study. Scand J Caring Sci 2002; 16: 393-398
11. Harvey PD, Green MF, Keefe RSE, Velligan DI: Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry 2004; 65: 361-372
12. Heaton RK, Chelune GJ, Taley JL, Kay GG, Curtiss G: Wisconsin Card Sorting Test Manual: Revised and Expanded. Odessa, FL: Psychological Assessment Resources, 1993
13. Hofer A, Baumgartner S, Edlinger M, Hummer M, Kemmler G, Rettenbacher MA et al Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects. Eur Psychiatry 2005; 20: 386-394
14. Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW: Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry 2004; 65: 932-939
15. Hofer A, Rettenbacher MA, Widschwendter CG, Kemmler G, Hummer M, Fleischhacker WW: Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. Eur Arch Psychiatry Clin Neurosci 2006; 256: 246-255
16. Hummer M, Huber J: Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin 2004; 20: 189-197
17. Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington, DC: Institute of Medicine, 2001
18. Karow A, Naber D: Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 2002; 162: 3-10
19. Karow A, Schnedler D, Naber D: What would the patient choose? Subjective comparison of atypical and typical neuroleptics. Pharmacopsychiatry 2006; 39: 47-51
20. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276
21. Kemmler G, Holzner B, Neudorfer C, Meise U, Hinterhuber H: General life satisfaction and domain-specific quality of life in chronic schizophrenic patients. Qual Life Res 1997; 6: 265-273
22. Kluge M, Wehmeier PM, Dittmann RW, Longer F, Czekalla J, Lehmann M et al A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being. Pharmacopsychiatry 2005; 38: 6-12
23. Larsen EB, Gerlach J: Subjective experience of treatment, side effects, mental state and quality of life in schizophrenic outpatients treated with depot neuroleptics. Acta Psychiatr Scand 1996; 96: 381-388
24. Lehrl S: Manual zum MWT-B. Erlangen: Verlag Dr. med. D. Straube, 1977
25. Leucht S, Pitschel-Walz G, Engel RR, Kissling W: Amisulpride, an unusual 'atypical' antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002; 159: 180-190
26. Lindenmayer JP, Bernstein-Hyman R, Grochowski S: Five-factor model of schizophrenia. J Nerv Ment Dis 1994; 182: 631-638
27. Lindenmayer JP, Grochowski S, Hyman RB: Five factor model of schizophrenia: replication across samples. Schizophr Res 1995; 14: 229-234
28. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU Side Effect Rating Scale - a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987; 334 (suppl): 1-100
29. Marwaha S, Johnson S: Schizophrenia and employment. A review. Soc Psychiatry Psychiatr Epidemiol 2004; 39: 337-349
30. McGurk SR, Powchick P: The central cholinergic system and cognitive dysfunction in schizophrenia. In Sharma T, Harvey PD, editors Cognition in Schizophrenia. New York NY: Oxford University Press, 2000, p. 266-285
31. Meltzer HY, McGurk SR: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25: 233-255
32. Mueser KT: Cognitive functioning, social adjustment, and long-term outcome in schizophrenia. In: Sharma T, Harvey PD, editors. Cognition in Schizophrenia. New York NY: Oxford University Press, 2000; 15-177
33. Ochoa S, Haro JM, Autonell J, Pendas A, Teba F, Marquez M et al Met and unmet needs of schizophrenia patients in a Spanish sample. Schizophr Bull 2003; 29: 201-210
34. Olivier B: Serotonergic mechanisms in aggression. Novartis Found Symp 2005; 268: 171-183 discussion 183-189, 242-253
35. Peuskens J, Möller HJ, Peuch A: Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacology 2002; 12: 305-310
36. Priebe S, Heinze M, Jäckel A: Berliner Bedürfnis Inventar (BeBI). FU Berlin: Abteilung für Sozialpsychiatrie, 1993
37. Rettenbacher MA: Disturbances of glucose and lipid metabolism during treatment with new generation antipsychotics. Curr Opin Psychiatry 2005; 18: 175-179
38. Rettenbacher MA, Eder-Ischia U, Bader A, Edlinger M, Hofer A, Hummer M et al QTc variability in schizophrenia patients treated with antipsychotics and healthy controls. J Clin Psychopharmacol 2005; 25: 206-210
39. Saleem P, Olie JP, Loo H: Social functioning and quality of life in the schizophrenic patient: advantes of amisulpride. Int Clin Psychopharmacol 2002; 17: 1-8
40. Sartorius N, Fleischhacker WW, Gjerris U, Kern U, Knapp M, Leonard BE et al The usefulness and use of second generation antipsychotic medications - an update. Curr Opin Psychiatry 2003; 16 (suppl 1): 1-44
41. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O et al Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presenaptic and limbic selectivity. J Pharmacol Exp Ther 1997; 280: 83-97
42. Slade M, Loftus L, Phelan M, Thornicroft G, Wykes T: CAN: The Camberwell Assessment of Need. Gaskell, London, 1999
43. The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 1998; 28: 551-558
44. Tollefson GD, Sanger TM, Lu Y, Thieme ME: Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55: 250-258
45. Van Oekelen D, Luyten WHML, Leysen JE: 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci 2003; 72: 2429-2449
46. Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, Kühn KU: Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology 2005; 30: 381-390
47. Weiden PJ, Shaw E, Mann JJ: Causes of neuroleptic noncompliance. Psychiatr Ann 1986; 16: 571-575
48. Woodward ND, Purdon SE, Meltzer HY, Zald DH: A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005; 8: 457-472
49. Zimmermann P, Fimm B: Testbatterie zur Aufmerksamkeitsprüfung (TAP), Version 1.. Herzogenrath: Vera Fimm/Psychologische Testsysteme, 2002